Roche, Biogen Idec, Inc. (Massachusetts) Report One Death In MS Drug Ocrelizumab Phase II Trial

BOSTON, Oct 15 (Reuters) - Roche Holding AG (ROG.VX) and Biogen Idec Inc (BIIB.O) reported data from a mid-stage trial of their experimental multiple sclerosis drug ocrelizumab on Friday that showed one patient died of an inflammatory condition.